Clinical improvement of photophobia with galcanezumab in episodic and chronic migraine
Abstract
Objective: This study aimed to evaluate changes in photophobia using the Turkish version of Utah Photophobia Symptom Impact Scale-12 (UPSIS-12) in patients with episodic (EM) and chronic migraine (CM) treated with galcanezumab, and to examine the relationship between photophobia, migraine outcomes, disability, and treatment response.
Background: Photophobia is one of the most bothersome symptoms (MBS) of migraine and may persist during both ictal and interictal periods, leading to substantial impairment in daily functioning. Despite the clear clinical relevance of photophobia, the specific effects of galcanezumab, a CGRP monoclonal antibody, on photophobia have not yet been fully elucidated.
Methods: This retrospective study, included patients with EM and CM treated with galcanezumab (240 mg loading dose followed by monthly 120 mg) for 3 months. Patients completed headache diaries and validated patient-reported outcome measures (PROMs) at baseline and monthly follow-up visits. Non-parametric tests, correlation analyses, and multivariable linear regression were performed.
Results: A total of 77 patients were enrolled, of whom 47 (89.3% female; mean age 39.5 ± 10.6 years) completed all study visits and were included in the final analysis. Over the study period, monthly headache days (MHDs) decreased from a median of 15 to 4 days by month 3 (p p p = 0.010). Significant improvements were also observed in ictal phonophobia, osmophobia, and cutaneous allodynia, whereas interictal…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.